LearnGlossaryMarketStocksSuperinvestorsSign in

STOK

Stoke Therapeutics, Inc.

Healthcare · $1.6B market cap

Verdict

We can't put a fair value on STOK right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-10.6% a year✗
Sales growth404.5% a year✓
Free cash flow growth—?
Return on invested capital-35.5%✗

Follow STOK

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 2 sales worth $170K. Why purchases matter

Sales

Ticho Barry

CHIEF MEDICAL OFFICER · 2026-09-01

Sold

$50K

Ticho Barry

CHIEF MEDICAL OFFICER · 2026-09-01

Sold

$120K

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works